GLI1-Altered Mesenchymal Tumors With ACTB or PTCH1 Fusion: A Molecular and Clinicopathologic Analysis
Modern Pathology · 2024-02 · 37 (2) · 100386
DOI: 10.1016/j.modpat.2023.100386 ↗Kurz gefasst
Fachartikel in der Zeitschrift Modern Pathology, 2024-02. Verfasst von Darcy A Kerr und 13 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pathology and Laboratory Medicine, Dartmouth-Hitchcock Medical Center, Lebanon, New Hampshire; Dartmouth Geisel School of Medicine, Han…. Hauptthemen laut MEDLINE: Neoplasms, Connective and Soft Tissue, Soft Tissue Neoplasms, Sarcoma. Die Arbeit wurde bisher 33-mal zitiert (Crossref) und nennt 38 Literaturangaben.
Abstract (Originalsprache)
Mesenchymal tumors with GLI1 fusions or amplifications have recently emerged as a distinctive group of neoplasms. The terms GLI1-altered mesenchymal tumor or GLI1-altered soft tissue tumor serve as a nosological category, although the exact boundaries/criteria require further elucidation. We examined 16 tumors affecting predominantly adults (median age: 40 years), without sex predilection. Several patients had tumors of longstanding duration (>10 years). The most common primary site was soft tissue (n = 9); other sites included epidural tissue (n = 1), vertebra (n = 1), tongue (n = 1), hard palate (n = 1), and liver (n = 1). Histologically, the tumors demonstrated multinodular growth of cytologically uniform, ovoid-to-epithelioid, occasionally short spindled cells with delicate intratumoral vasculature and frequent myxoid stroma. Mitotic activity ranged from 0 to 8 mitoses/2 mm2 (mean 2). Lymphovascular invasion/protrusion of tumor cells into endothelial-lined vascular spaces was present or suspected in 6 cases. Necrosis, significant nuclear pleomorphism, or well-developed, fascicular spindle-cell growth were absent. Half demonstrated features of the newly proposed subset, "distinctive nested glomoid neoplasm." Tumors were consistently positive for CD56 (n = 5/5). A subset was stained with S100 protein (n = 7/13), SMA (n = 6/13), keratin (n = 2/9), EMA (n = 3/7), and CD99 (n = 2/6). Tumors harbored ACTB::GLI1 (n = 15) or PTCH1::GLI1 (n = 1) fusions. The assays used did not capture cases defined by GLI1 amplification. We also identified recurrent cytogenetic gains (1q, 5, 7, 8, 12, 12q13.2-ter, 21, and X). For patients with available clinical follow-up (n = 8), half were disease free. Half demonstrated distant metastases (lungs, bone, or soft tissue). Of cases without follow-up (n = 8), 2 were known recurrences, and 1 was presumed metastasis. Our results imply a more aggressive biological potential than currently reported. Given the possibility for metastasis and disease progression, even in cytologically bland, nested tumors, close clinical surveillance, akin to that for sarcoma management, may be indicated. The term GLI1-altered mesenchymal tumor with malignant potential is proposed.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pathology and Laboratory Medicine, Dartmouth-Hitchcock Medical Center, Lebanon, New Hampshire; Dartmouth Geisel School of Medicine, Hanover, New Hampshire. Electronic address: Darcy.A.Kerr@hitchcock.org.
- Department of Pathology, MD Anderson Cancer Center, Houston, TX; Now with Department of Pathology and Laboratory Medicine, Dartmouth-Hitchcock Medical Center, Lebanon, New Hampshire; Now with Dartmouth Geisel School of…
- Foundation Medicine, Inc., Cambridge, Massachusetts.
- Department of Pathology and Laboratory Medicine, Dartmouth-Hitchcock Medical Center, Lebanon, New Hampshire.
- Department of Pathology, Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts.
- Department of Pathology, Keck School of Medicine, University of Southern California, Los Angeles, California.
Zitieren
APA
Kerr, D. A., Cloutier, J. M., Margolis, M., Mata, D. A., Rodrigues Simoes, N. J., Faquin, W. C., Dias-Santagata, D., Chopra, S., Charville, G. W., Wangsiricharoen, S., Lazar, A. J., Wang, W. L., Rosenberg, A. E., & Tse, J. Y. (2024). GLI1-Altered Mesenchymal Tumors With ACTB or PTCH1 Fusion: A Molecular and Clinicopathologic Analysis. Modern Pathology, 37(2), 100386. https://doi.org/10.1016/j.modpat.2023.100386
Vancouver
Kerr DA, Cloutier JM, Margolis M, Mata DA, Rodrigues Simoes NJ, Faquin WC, et al. GLI1-Altered Mesenchymal Tumors With ACTB or PTCH1 Fusion: A Molecular and Clinicopathologic Analysis. Modern Pathology. 2024;37(2):100386. doi:10.1016/j.modpat.2023.100386
BibTeX
@article{Kerr2024,
author = {Kerr, Darcy A and Cloutier, Jeffrey M and Margolis, Matthew and Mata, Douglas A and Rodrigues Simoes, Nathalie J and Faquin, William C and Dias-Santagata, Dora and Chopra, Shefali and Charville, Gregory W and Wangsiricharoen, Sintawat and Lazar, Alexander J and Wang, Wei-Lien and Rosenberg, Andrew E and Tse, Julie Y},
title = {GLI1-Altered Mesenchymal Tumors With ACTB or PTCH1 Fusion: A Molecular and Clinicopathologic Analysis},
journal = {Modern Pathology},
year = {2024},
volume = {37},
number = {2},
pages = {100386},
doi = {10.1016/j.modpat.2023.100386}
}
EUVIMED